Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 2017-11-01 (8 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MORET-LOING-ET-ORVANNE (77250), Seine-et-Marne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE TYSSANDIER & BOSTON : revenue, balance sheet and financial ratios
PHARMACIE TYSSANDIER & BOSTON is a French company
founded 8 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MORET-LOING-ET-ORVANNE (77250),
this company of category PME
shows in 2022 a revenue of 2.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE TYSSANDIER & BOSTON (SIREN 832386619)
Indicator
2024
2023
2022
2021
2020
2019
2018
Revenue
N/C
N/C
2 898 234 €
N/C
N/C
N/C
N/C
Net income
117 481 €
135 426 €
188 733 €
257 000 €
157 661 €
122 585 €
-22 568 €
EBITDA
N/C
N/C
284 573 €
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
6.5%
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE TYSSANDIER & BOSTON generates positive net income of 117 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
117 481 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 1161%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 7%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
1160.752%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
6.962%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE TYSSANDIER & BOSTON
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
Debt ratio
729.027
443.873
285.574
169.114
112.062
86.138
1160.752
Financial autonomy
10.932
16.323
22.019
31.838
40.063
45.381
6.962
Repayment capacity
None
None
None
None
5.345
None
None
Cash flow / Revenue
None%
None%
None%
None%
6.897%
None%
None%
Sector positioning
Debt ratio
1160.752024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average+16 pts over 3 years
In 2024, the debt ratio of PHARMACIE TYSSANDIER & BO... (1160.75) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
6.96%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Watch-18 pts over 3 years
In 2024, the financial autonomy of PHARMACIE TYSSANDIER & BO... (7.0%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
Repayment capacity
5.34 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of PHARMACIE TYSSANDIER & BO... (5.34) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 220.07. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
220.069
Liquidity indicators evolution PHARMACIE TYSSANDIER & BOSTON
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
204.162
196.073
184.095
220.927
208.471
202.568
220.069
Interest coverage
None
None
None
None
4.225
None
None
Sector positioning
Liquidity ratio
220.072024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Good+9 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE TYSSANDIER & BO... (220.07) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
4.22x2022
2022
Q1: 0.74x
Med: 2.5x
Q3: 5.15x
Good
In 2022, the interest coverage of PHARMACIE TYSSANDIER & BO... (4.2x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE TYSSANDIER & BOSTON
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
262 696 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
31
0
0
Customer payment term (days)
0
0
0
0
5
0
0
Supplier payment term (days)
0
0
0
0
46
0
0
Positioning of PHARMACIE TYSSANDIER & BOSTON in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE TYSSANDIER & BOSTON is estimated at
1 640 121 €
(range 1 142 154€ - 2 453 715€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1142k€1640k€2453k€
1 640 121 €Range: 1 142 154€ - 2 453 715€
NAF 5 année 2024
Valuation method used
Net Income Multiple
117 481 €
×
14.0x
=1 640 122 €
Range: 1 142 155€ - 2 453 716€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE TYSSANDIER & BOSTON with other companies in the same sector:
Frequently asked questions about PHARMACIE TYSSANDIER & BOSTON
What is the revenue of PHARMACIE TYSSANDIER & BOSTON ?
The revenue of PHARMACIE TYSSANDIER & BOSTON in 2022 is 2.9 M€.
Is PHARMACIE TYSSANDIER & BOSTON profitable?
Yes, PHARMACIE TYSSANDIER & BOSTON generated a net profit of 117 k€ in 2024.
Where is the headquarters of PHARMACIE TYSSANDIER & BOSTON ?
The headquarters of PHARMACIE TYSSANDIER & BOSTON is located in MORET-LOING-ET-ORVANNE (77250), in the department Seine-et-Marne.
Where to find the tax return of PHARMACIE TYSSANDIER & BOSTON ?
The tax return of PHARMACIE TYSSANDIER & BOSTON is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE TYSSANDIER & BOSTON operate?
PHARMACIE TYSSANDIER & BOSTON operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart